美国癌症联合委员会第8版前列腺癌分期分类的独立验证
研究基于梅奥诊所1987至2011年间13,839例根治性前列腺切除术患者,独立验证AJCC第8版前列腺癌分期分类。结果显示pT2亚分类区分能力有限,PSA≥20 ng/ml或Gleason分级分组5的患者预后分别与第7版III期或更差,支持新版分类的调整。
要点
- pT2亚分类对生化复发、转移和癌特异性生存的区分能力有限,c-index分别为0.531、0.545、0.525。
- 第7版II期且PSA≥20 ng/ml患者15年生化复发无生存率42.2%,低于PSA<20 ng/ml者的58.8%。
- 第7版II期且Gleason分级分组5患者15年癌特异性生存率73.0%,低于第7版III期患者的83.4%。
核心结论
- 研究数据支持新版AJCC分类中的变更。
研究设计与样本
- 研究为独立验证,纳入梅奥诊所1987至2011年间13,839例接受根治性前列腺切除术的男性,来自机构注册数据库。
主要发现
- 中位随访10.5年(IQR 7.1-15.3)。
- pT2前列腺癌患者中,亚分类对生化复发无生存、转移无生存和癌特异性生存的区分能力有限,c-index分别为0.531、0.545和0.525。
- 第7版II期且PSA≥20 ng/ml患者相比第7版II期且PSA<20 ng/ml患者,15年生化复发无生存率42.2% vs 58.8%、转移无生存率78.2% vs 88.8%、癌特异性生存率88.0% vs 94.4%,均p<0.001。
- 第7版II期且PSA≥20 ng/ml患者相比第7版III期患者,15年生化复发无生存率42.2% vs 31.3%(p=0.007)、转移无生存率78.2% vs 68.0%(p<0.001)、癌特异性生存率88.0% vs 83.4%(p=0.01)。
- 第7版II期且Gleason分级分组5患者相比第7版II期且Gleason分级分组1-4患者,15年生化复发无生存率37.1% vs 57.9%(p<0.001)、转移无生存率63.8% vs 88.5%(p<0.001)、癌特异性生存率73.0% vs 94.3%(p<0.001);相比第7版III期患者,15年癌特异性生存率73.0% vs 83.4%(p=0.005)。
关键数值与推荐
- AJCC第8版取消了pT2亚分类(原文未给出具体推荐等级)。
- AJCC第8版将PSA≥20 ng/ml且第7版II期患者重新分类为III-A期(原文未给出具体推荐等级)。
- AJCC第8版将Gleason分级分组5且第7版II期患者重新分类为III-C期(原文未给出具体推荐等级)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to independently validate the AJCC (American Joint Committee on Cancer) 8th edition prostate cancer staging classification, which includes the elimination of pT2 subcategories and the reclassification of patients with prostate specific antigen 20 ng/ml or greater and Gleason Grade Group 5 as stage groups III-A and III-C, respectively. MATERIALS AND METHODS: We identified 13,839 men who underwent radical prostatectomy at Mayo Clinic between 1987 and 2011 from our institutional registry. Outcomes included biochemical recurrence-free, metastasis-free and cancer specific survival. Kaplan-Meier analyses and Cox regression models with the c-index were used. RESULTS: Median followup was 10.5 years (IQR 7.1-15.3). Among patients with pT2 prostate cancer the subclassification demonstrated limited discrimination for biochemical recurrence-free, metastasis-free and cancer specific survival (c-index 0.531, 0.545 and 0.525, respectively). At the same time patients with 7th edition stage group II prostate cancer and prostate specific antigen 20 ng/ml or greater had significantly worse 15-year biochemical recurrence-free survival (42.2% vs 58.8%), metastasis-free survival (78.2% vs 88.8%) and cancer specific survival (88.0% vs 94.4%, all p <0.001) than patients with 7th edition stage group II prostate cancer and prostate specific antigen less than 20 ng/ml. However, patients with 7th edition stage group II prostate cancer and prostate specific antigen 20 ng/ml or greater had significantly better 15-year biochemical recurrence-free survival (42.2% vs 31.3%, p = 0.007), metastasis-free survival (78.2% vs 68.0%, p <0.001) and cancer specific survival (88.0% vs 83.4%, p = 0.01) than patients with 7th edition stage group III. Also, patients with 7th edition stage group II prostate cancer and Gleason Grade Group 5 had significantly worse 15-year biochemical recurrence-free survival (37.1% vs 57.9%, p <0.001), metastasis-free survival (63.8% vs 88.5%, p <0.001) and cancer specific survival (73.0% vs 94.3%, p <0.001) than patients with 7th edition stage group II prostate cancer and Gleason Grade Group 1-4 as well as worse 15-year cancer specific survival (73.0% vs 83.4%, p = 0.005) than patients with 7th edition stage group III prostate cancer. CONCLUSIONS: Our data support the changes in the new AJCC classification.
引用
- Bhindi B, Karnes RJ, Rangel LJ, et al. Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification. J Urol. 2017. PMID: 28669765. doi:10.1016/j.juro.2017.06.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。